Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has received marketing approval from the FDA for a new injection formulation of its Debiopharm SA co-developed anticancer treatment, Eloxatin, in colon cancer.
Subscribe to our email newsletter
Eloxatin (oxaliplatin) injection is a clear, preservative-free solution available in 50mg and 100mg doses. Eloxatin injection offers additional benefit and convenience as it involves fewer steps in the administration of Eloxatin.
Eloxatin injection, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor, and for the treatment of advanced carcinoma of the colon or rectum.
Eloxatin was co-developed by Sanofi-Aventis and Debiopharm SA and is currently marketed by Sanofi-Aventis in more than 60 countries.
In the US, the Eloxatin-based regimen received approval for the first-line treatment of advanced carcinoma of the colon or rectum on January 9, 2004 and for the adjuvant treatment of stage III colon cancer on November 4, 2004.
An extensive worldwide clinical development program is ongoing to explore the potential benefits of Eloxatin in other types of cancer.